Get the Stockscreener App
4.14
0.72%
-0.03
Kala Bio Inc stock is traded at $4.14, with a volume of 39,447.
It is down -0.72% in the last 24 hours and up +20.00% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$4.17
Open:
$4.16
24h Volume:
39,447
Relative Volume:
0.72
Market Cap:
$24.00M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.332
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+11.29%
1M Performance:
+20.00%
6M Performance:
-39.03%
1Y Performance:
-36.99%
1-Day Range:
$3.76
$4.16
1-Week Range:
$3.50
$4.40
52-Week Range:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
4.14 | 24.00M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Millennium Management LLC Decreases Stake in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Kala Bio director Mark Iwicki sells $40,638 in stock - Investing.com India
KALA BIO Executives Sell Shares - TradingView
KALA BIO (NASDAQ:KALA) Given “Outperform” Rating at Oppenheimer - Defense World
KALA: Oppenheimer Announces Outperform Rating for Kala Bio | KALA Stock News - GuruFocus
KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | KALA Stock News - GuruFocus
KALA BIO to Present at Jefferies Global Healthcare Conference - The Manila Times
KALA BIO to Reveal Latest Eye Disease Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan
Q1 Earnings Estimate for KALA BIO Issued By HC Wainwright - Defense World
HC Wainwright Lowers KALA BIO (NASDAQ:KALA) Price Target to $12.00 - Defense World
Kala Bio stock target cut to $12 by H.C. Wainwright, retains buy - Investing.com Nigeria
KALA Stock: HC Wainwright & Co. Adjusts Price Target for Kala Bi - GuruFocus
KALA Stock: HC Wainwright & Co. Adjusts Price Target for Kala Bio | KALA Stock News - GuruFocus
KALA Price Target Reduced by H.C. Wainwright After Q3 Results | - GuruFocus
KALA Price Target Reduced by H.C. Wainwright After Q3 Results | KALA Stock News - GuruFocus
KALA BIO: Q1 Earnings Snapshot - New Haven Register
Persistent Epithelial Defect Market on Track for Major - openPR.com
KALA Focuses on Advancing KPI-012 Development Amid Pivotal Trials | KALA Stock News - GuruFocus
Kala Pharmaceuticals reports Q1 EPS ($1.41) vs ($4.20) last year - TipRanks
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Algorhythm Holdings to Announce its Financial Results for the First Quarter 2025 - The Manila Times
KALA's PCED Drug Could Reach 100,000 PatientsQ3 Trial Results Coming - Stock Titan
Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Research Analysts Set Expectations for Datadog Q2 Earnings - Defense World
B. Riley Issues Negative Estimate for Cadre Earnings - Defense World
HC Wainwright Issues Positive Forecast for Clene Earnings - Defense World
Equities Analysts Issue Forecasts for Cryoport Q2 Earnings - Defense World
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Q2 EPS Estimate for Cogent Biosciences Lifted by Analyst - Defense World
Q2 EPS Estimates for Core Scientific Lifted by HC Wainwright - Defense World
B. Riley Issues Negative Estimate for Fox Factory Earnings - Defense World
KALA BIO (KALA) Projected to Post Quarterly Earnings on Tuesday - Defense World
Q2 Earnings Forecast for Cryoport Issued By Leerink Partnrs - Defense World
KALA BIO (KALA) Projected to Post Earnings on Tuesday - Defense World
Fluence Energy, Inc. (NASDAQ:FLNC) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Dimensional Fund Advisors LP Sells 5,772 Shares of Turning Point Brands, Inc. (NYSE:TPB) - Defense World
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Geode Capital Management LLC Has $426,000 Stake in Sidus Space, Inc. (NASDAQ:SIDU) - Defense World
Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World
Geode Capital Management LLC Boosts Holdings in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Geode Capital Management LLC Has $403,000 Stake in Mobix Labs, Inc. (NASDAQ:MOBX) - Defense World
Wix.com Ltd [WIX] Insider Activity: An Update for Investors - knoxdaily.com
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
Recent Insider Activity Could Benefit Insperity Inc (NSP) - knoxdaily.com
Analyzing Kala Bio Inc (KALA) After Recent Trading Activity - knoxdaily.com
International Business Machines Corp [IBM] Stock sold by Insider Thomas Robert David for $6.72 million - knoxdaily.com
Aurora Cannabis Inc [ACB] Investment Guide: What You Need to Know - knoxdaily.com
Insider Sale Alert: Angi Inc [ANGI] – Is it Time to sell? - knoxdaily.com
Kala Bio Inc (KALA) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Kala Bio Inc (KALA) Stock: A Year of Market Fluctuations - investchronicle.com
Piper Sandler gives a Neutral recommendation for RxSight Inc (RXST) - knoxdaily.com
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 03 '25 |
Sale |
3.74 |
2,850 |
10,659 |
65,731 |
| Bazemore Todd | SEE REMARKS |
Jun 03 '25 |
Sale |
3.74 |
3,390 |
12,679 |
87,757 |
| Brazzell Romulus K | SEE REMARKS |
Jun 03 '25 |
Sale |
3.74 |
3,687 |
13,789 |
87,949 |
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):